danДоклады Национальной академии наук БеларусиDoklady of the National Academy of Sciences of Belarus1561-83232524-2431The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1561-8323-2023-67-1-59-65dan-1112Research ArticleМЕДИЦИНАMEDICINEЭкспрессия муцинов при раке печениMucin expression in liver cancerhttps://orcid.org/0000-0002-1348-8688КузнецовО. Е.KuznetsovO. E.

Кузнецов Олег Евгеньевич – канд. биол. наук, доцент, директор.

пл. Антония Тызенгауза, 7, 230023, Гродно

Kuznetsov Oleg E. – Ph. D. (Medicine), Associate Professor, Director

7, Anthony Tyzengauz Square, 230023, Grodno

olegkuznetsov@inbox.ruhttps://orcid.org/0000-0002-9366-6789ЦыркуновВ. М.TsyrkunovV. M.

Цыркунов Владимир Максимович – д-р мед. наук, профессор

ул. Горького, 80, 230009, Гродно 

Tsyrkunov Vladimir M. – D. Sc. (Medicine), Professor

80, Gorky Str., 230009, Grodno

tvm111@mail.ruКеримоваС. Ш.KerimovaS. Sh.

Керимова Сапартач Ширдогдыевна – врач патологоанатом

Бульвар Ленинского Комсомола,54а, 230030, Гродно

Kerimova Sapartach Sh. – Pathologist.

54a, Leninsky Komsomol Boulevard, 230030, Grodno

kerimowa1993@bk.ruИнститут биохимии биологически активных соединений Национальной академии наук Беларуси; Гродненский государственный медицинский университетInstitute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of BelarusГродненский государственный медицинский университетGrodno State Medical UniversityГродненское областное клиническое патологоанатомическое бюроGrodno Regional Clinical Pathological Bureau2023040320236715965Copyright © Кузнецов О.Е., Цыркунов В.М., Керимова С.Ш., 20232023Кузнецов О.Е., Цыркунов В.М., Керимова С.Ш.Kuznetsov O.E., Tsyrkunov V.M., Kerimova S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://doklady.belnauka.by/jour/article/view/1112

Рост заболеваемости, трудности ранней диагностики и высокий уровень летальности пациентов при раке печени (РП) определяют актуальность изучения механизмов его развития. Оценена экспрессия высокомолекулярных гликопротеинов MUC-1, MUC-13 при РП. Предметом исследования были 65 архивных образцов тканей опухоли печени и 34 пробы сыворотки крови у пациентов с морфологически подтвержденным РП. Возраст обследуемых составил 26–97 лет. Исследование уровня антител к MUC-1 и MUC-13 проводили методом ИФА. Установлены пределы референтных значений MUC-1 (0,250 ± 0,10 нг/мл) и MUC-13 (0,321 ± 0,13 нг/мл) в сыворотке крови у здоровых лиц. Концентрация сывороточных антител к MUC-1 и MUC-13 у пациентов с РП была значимо выше показателей здоровых лиц. Содержание MUC-1 и MUC-13 в ткани опухоли печени было более высоким, чем в сыворотке крови практически здоровых лиц и пациентов с РП. При подтвержденном диагнозе РП уровень антител к MUC-1, превышающий в сыворотке крови 0,373 нг/мл, и уровень антител к MUC-13 более 0,939 нг/мл может указывать на высокий риск наличия опухолевого процесса.

Increasing incidence, difficulties in early diagnosis, and a high mortality rate in liver cancer (LC) determine the relevance of studying the mechanisms of its development. The aim of the work is to evaluate the expression of high molecular weight glycoproteins MUC-1, MUC-13 in liver cancer. The object of study is LC tissue samples of 65 patients from the archives and 34 blood serum samples from patients with morphologically confirmed LC. The age of subjects was 26– 97 years. The level of antibodies to MUC-1 and MUC-13 was studied by ELISA. The reference value ranges of MUC-1 (0.250 ± 0.10 ng/ml) and MUC-13 (0.321 ± 0.13 ng/ml) in the blood serum of healthy individuals were established. The concentration of antibodies to MUC-1 and MUC-13 in the blood serum in RP was significantly higher than that in practically healthy individuals. The concentration of MUC-1 and MUC-13 in the LC tumor tissue was higher than that in the blood serum of apparently healthy individuals and LC patients. With a confirmed LC diagnosis, the level of antibodies to MUC-1 in the blood serum, which exceeds 0.373 ng/ml, and the level of antibodies to MUC-13, which is more than 0.939 ng/ml, may indicate a high risk of a tumor process.

муцинсывороткатканьракпеченьmucinserumtissuecancerliverReferencesКузнецов, О. Е. Вирус-ассоциированный гепатоцеллюлярный рак печени / О. Е. Кузнецов, В. М. Цыркунов // Гепатология и гастроэнтерология. – 2021. – Т. 5, № 1. – С. 17–24. https://doi.org/10.25298/2616-5546-2021-5-1-17-24Kuznetsov O. E., Tsyrkunov V. M. Virus-associated hepatocellular liver cancer. Gepatologiya i gastroenterologiya = Hepatology and gastroenterology, 2021, vol. 5, no. 1, pp. 17–24 (in Russian). https://doi.org/10.25298/2616-5546-2021-5-1-17-24Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries / H. Sung [et al.] // CA: Cancer J. Clin. – 2021. – Vol. 71, N 3. – P. 209–249. https://doi.org/10.3322/caac.21660Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer Journal for Clinicians, 2021, vol. 71, no. 3, pp. 209–249. https://doi.org/10.3322/caac.21660Globocan 2020 – Global Cancer Observatory [Electronic resource]. – Mode of access: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. – Date of access: 21.03.2022.Globocan 2020 – Global Cancer Observatory. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf (accessed 21 March 2022).Global burden of cancers attributable to infections in 2012: a synthetic analysis / M. Plummer [et al.] // Lancet Glob. Health. – 2016. – Vol. 4, N 9. – P. 609–616. https://doi.org/10.1016/s2214-109x(16)30143-7Plummer M., de Martel C., Vignat J., Ferlay J., Bray F., Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health, 2016, vol. 4, no. 9, pp. 609–616. https://doi.org/10.1016/s2214-109x(16)30143-7Challenges in liver cancer and possible treatment approaches / D. Anwanwan [et al.] // Biochim. Biophys. Acta – Rev. Cancer. – 2020. – Vol. 1873, N 1. – Art. 188314. https://doi.org/10.1016/j.bbcan.2019.188314Anwanwan D., Singh S. K., Singh S., Saikam V., Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 2020, vol. 1873, no. 1, art. 188314. https://doi.org/10.1016/j.bbcan.2019.188314Kasprzak, A. Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis / A. Kasprzak, A. Adamek // Int. J. Mol. Sci. – 2019. – Vol. 20, N 6. – P. 1288. https://doi.org/10.3390/ijms20061288Kasprzak A., Adamek A. Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis. International Journal of Molecular Sciences, 2019, vol. 20, no. 6, pp. 1288. https://doi.org/10.3390/ijms20061288Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases / S. K. Behera [et al.] // Glycoconj. J. – 2015. – Vol. 32, N 8. – P. 575–613. https://doi.org/10.1007/s10719-015-9606-6Behera S. K., Praharaj A. B., Dehury B., Negi S. Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases. Glycoconjugate Journal, 2015, vol. 32, no. 8, pp. 575–613. https://doi.org/10.1007/s10719-015-9606-6Weizmann Institute of Science. GeneCards [Electronic resource]. – Mode of access: https://www.genecards.org/. – Date of access: 22.03.2022.Weizmann Institute of Science, GeneCards (2021). Available at: https://www.genecards.org/ (accessed 22 March 2022).Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets / S. S. Dhanisha [et al.] // Crit. Rev. Oncol. Hematol. – 2018. – Vol. 122. – P. 98–122. https://doi.org/10.1016/j.critrevonc.2017.12.006Dhanisha S. S., Guruvayoorappan C., Drishya S., Abeesh P. Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Critical Reviews in Oncology/Hematology, 2018, vol. 122, pp. 98–122. https://doi.org/10.1016/j.critrevonc.2017.12.006Composition and functional role of the mucus layers in the intestine / M. E. Johansson [et al.] // Cell. Mol. Life Sci. – 2011. – Vol. 68, N 22. – P. 3635–3641. https://doi.org/10.1007/s00018-011-0822-3Johansson M. E., Ambort D., Pelaseyed T., Schütte A., Gustafsson J. K., Ermund A., Subramani D. B., Holmén-Larsson J. M., Thomsson K. A., Bergström J. H., van der Post S., Rodriguez-Piñeiro A. M., Sjövall H., Bäckström M., Hansson G. C. Composition and functional role of the mucus layers in the intestine. Cellular and Molecular Life Sciences, 2011, vol. 68, no. 22, pp. 3635–3641. https://doi.org/10.1007/s00018-011-0822-3Mucins in inflammatory bowel diseases and colorectal cancer / Y. H. Sheng [et al.] // J. Gastroenterol. Hepatol. – 2012. – Vol. 27, N 1. – P. 28–38. https://doi.org/10.1111/j.1440-1746.2011.06909.xSheng Y. H., Hasnain S. Z., Florin T. H., McGuckin M. A. Mucins in inflammatory bowel diseases and colorectal cancer. Journal of Gastroenterology and Hepatology, 2012, vol. 27, no. 1, pp. 28–38. https://doi.org/10.1111/j.1440-1746.2011.06909.xMUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide / J. J. Du [et al.] // Front Chem. – 2022. – Vol. 10. – Art. 814880. https://doi.org/10.3389/fchem.2022.814880Du J. J., Zhou S. H., Cheng Z. R., Xu W. B., Zhang R. Y., Wang L. S., Guo J. MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide. Frontiers in Chemistry, 2022, vol. 10, art. 814880. https://doi.org/10.3389/fchem.2022.814880Wi, D. H. Mucin in cancer: a stealth cloak for cancer cells / D. H. Wi, J. H. Cha, Y. S. Jung // BMB Rep. – 2021. – Vol. 54, N 7. – P. 344–355. https://doi.org/10.5483/bmbrep.2021.54.7.064Wi D. H., Cha J. H., Jung Y. S. Mucin in cancer: a stealth cloak for cancer cells. BMB Reports, 2021, vol. 54, no. 7, pp. 344–355. https://doi.org/10.5483/bmbrep.2021.54.7.064Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue / S. F. Yuan [et al.] // World J. Gastroenterol. – 2005. – Vol. 11, N 30. – P. 4661–4666. https://doi.org/10.3748/wjg.v11.i30.4661Yuan S. F., Li K. Z., Wang L., Dou K. F., Yan Z., Han W., Zhang Y. Q. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World Journal of Gastroenterology, 2005, vol. 11, no. 30, pp. 4661–4666. https://doi.org/10.3748/wjg.v11.i30.4661MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways / P. Tiemin [et al.] // J. Hepatol. – 2020. – Vol. 72, N 4. – P. 761–773. https://doi.org/10.1016/j.jhep.2019.11.021Tiemin P., Fanzheng M., Peng X., Jihua H., Ruipeng S., Yaliang L., Yan W., Junlin X., Qingfu L., Zhefeng H., Jian L., Zihao G., Guoxing L., Boshi S., Ming Z., Qinghui M., Desen L., Lianxin L. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Journal of Hepatology, 2020, vol. 72, no. 4, pp. 761–773. https://doi.org/10.1016/j.jhep.2019.11.021

The authors declare that there are no conflicts of interest present.